NEW YORK (TheStreet) -- Shares of Mallinckrodt (MNK) are up 0.07% to $88.49 ahead of reporting its 2014 fourth quarter earnings before tomorrow's market open. Here's what analysts are expecting from the global specialty pharmaceuticals company.
Analysts expect revenue for the fourth quarter of $757.86 million and earnings of $1.41 per share for the Dublin-based Mallinckrodt. The company reported $552.2 million in revenue and $1.02 of earnings per share a year ago in the fourth quarter of 2013.
In the third quarter of this year, Mallinckrodt posted earnings per share of $1.20 cents, above estimates of 87 cents. Its third quarter revenue jumped to $653 million, up 14.6% from $570 million for the same period a year earlier.
The company's core strengths include the acquisition and management of highly regulated raw materials, deep regulatory expertise, and specialized chemistry, formulation and manufacturing capabilities.
Separately, TheStreet Ratings team rates MALLINCKRODT PLC as a Sell with a ratings score of D+. TheStreet Ratings Team has this to say about their recommendation:
"We rate MALLINCKRODT PLC (MNK) a SELL. This is driven by a few notable weaknesses, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. Among the areas we feel are negative, one of the most important has been very high debt management risk by most measures."
You can view the full analysis from the report here: MNK Ratings Report